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ABSTRACT
The standard of care for breast cancer has gradually evolved from empirical 
treatments based on clinical-pathological characteristics to the use of targeted 
approaches based on the molecular profile of the tumor. Consequently, an increasing 
number of molecularly targeted drugs have been developed. These drugs target 
specific alterations, called driver mutations, which confer a survival advantage to 
cancer cells. To date, the main challenge remains the identification of predictive 
biomarkers for the selection of the optimal treatment. On this basis, we evaluated 
a panel of 25 genes involved in the mechanisms of targeted treatment resistance, 
in 16 primary breast cancers and their matched recurrences, developed during 
treatment. Overall, we found a detection rate of mutations higher than that described 
in the literature. In particular, the most frequently mutated genes were ERBB2 and 
those involved in the PI3K/AKT/mTOR and the MAPK signaling pathways. The study 
revealed substantial discordances between primary tumors and metastases, stressing 
the need for analysis of metastatic tissues at recurrence. We observed that 85.7% of 
patients with an early-stage or locally advanced primary tumor showed at least one 
mutation in the primary tumor. This finding could explain the subsequent relapse and 
might therefore justify more targeted adjuvant treatments. Finally, the mutations 
detected in 50% of relapsed tissues could have guided subsequent treatment choices 
in a different way. This study demonstrates that mutation events may be present 
at diagnosis or arise during cancer treatment. As a result, profiling primary and 
metastatic tumor tissues may be a major step in defining optimal treatments.
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INTRODUCTION
Breast cancer (BC) is a heterogeneous disease that 
develops and progresses from alterations in the genes 
that govern cell growth, proliferation and differentiation 
[1, 2]. At the same time, these molecular alterations are 
responsible for primary and secondary treatment resistance 
and may represent a major limitation to cancer treatment 
efficacy. In the last two decades, increasing knowledge of 
genomic abnormalities associated with gain of function 
or downstream signal activation involved in BC evolution 
allowed for new therapeutic approaches “tailored” on 
identified molecular alterations. The revolutionary era 
of targeted therapy shifted the classic paradigm of BC 
treatment from an approach based on pathological and 
clinical characteristics [3] to personalized medicine. 
This is based on the match between molecular alteration 
conferring a survival advantage to cancer cells, and the 
targeted drug [4]. An increasing number of molecularly 
targeted drugs are currently available for clinical practice 
or in the context of clinical trials. Nowadays, the main 
challenge remains the identification of predictive 
biomarkers for the selection of optimal treatment, in 
order to spare patients from treatment-associated side 
effects and to minimize the overall cost [5]. On this basis, 
parallel to the development of new therapeutic strategies, 
researches are looking for molecular biomarkers able to 
predict response to those treatments. For some of these 
targeted therapies, predictive biomarkers have already 
been identified in clinical trials [6]. In particular, PIK3CA 
mutations have already been shown to predict sensitivity to 
Everolimus [7], Buparlisib [8] and Taselisib [9] as well as 
resistance to Lapatinib [10]. AKT1 mutations can predict 
sensitivity to Everolimus [7], while ESR1 mutations 
can predict sensitivity to Fulvestrant and resistance to 
Exemestane [11]. Furthermore, HER2-negative patients 
with an ERBB2 somatic mutation are potentially good 
candidates for HER2-targeted therapy [12, 13], as already 
shown by Neratinib in two recently published clinical 
trials [14, 15]. 
The main purpose of our study was to investigate 
the mechanisms of treatment resistance in a sample of 
metastatic BC patients. Since BC behaves as an evolving 
entity, with metastases acquiring different biological 
profiles as compared to their matched primary tumors 
[16, 17], we evaluated a panel of 25 genes involved in the 
mechanisms of endocrine and targeted treatment resistance 
in paired BC samples (primary and recurrence) of patients 
with metastatic BC. 
RESULTS
Patient and sample characteristics
The tumor characteristics of the 16 patients enrolled 
in the study are described in Table 1. The median age at 
BC diagnosis was 57 years (range 35–81). Following the 
classification proposed in the 13th St Gallen International 
Breast Cancer Conference in 2013, seven patients 
(43.75%) were diagnosed with Luminal A-like BC. This 
means estrogen-receptor positive, progesterone-receptor 
≥20%, HER2 negative, and low levels of MIB1 (<20%). 
The other 9 patients (56.25%) had Luminal B-like BC 
(estrogen-receptor positive and progesterone-receptor 
<20% or HER2 positive or levels of MIB1 ≥20%). Of 
these patients, 4 were Luminal B-like HER2 positive. 
At presentation, 3 patients (18.75%) had Stage IA 
BC, 4 patients (25%) had Stage IIA, 2 patients (12.5%) 
had Stage IIB, 3 (18.75%) had Stage IIIA, 1 (6.25%) 
had Stage IIIB, 1 (6.25%) had Stage IIIC and 2 (12.5%) 
had Stage IV disease. The most common sites of 
relapse were lymph-nodes (9 patients, 56.25%), bones 
(7 patients, 43.75%) and skin (6 patients, 37.5%). As 
regards the biopsy of the relapse/metastasis, 7 patients 
(43.75%) underwent skin or soft tissues biopsy, 5 patients 
(31.25%) had lymph-node biopsy, 2 patients (12.5%) 
had liver biopsy, one patient (6.25%) underwent single 
lung metastasis resection, and lastly one patient (6.25%) 
underwent ipsilateral mastectomy for a local recurrence. 
In 8 cases (50%), the relapse/metastasis maintained the 
same immunohistochemical characteristics [i.e. the same 
hormone receptors (HR) and HER2 status] of the primary 
tumor, whereas 8 (50%) changed during progression. 
More specifically, estrogen receptor (ER) and progesteron 
receptor (PR) were considered positive when ≥1%, 
according to the last ASCO/CAPS Guidelines [18]. Rates 
of discordance were 18.75%, 31.25% and 6.25% for ER, 
PR and HER2, respectively. 
Predictive value of primary tumor mutations
Two patients (12.5%) received neoadjuvant 
chemotherapy (anthracycline and taxane-based), whereas 
8 patients (50%) received adjuvant chemotherapy 
(1 anthracycline and taxane-based, 3 anthracycline-based, 
2 taxane-based and 2 patients with cyclophosphamide, 
methotrexate and fluorouracil). One patient (Patient 12) 
received endocrine treatment (letrozole and fulvestrant) 
with neoadjuvant purposes, but she achieved no response 
and underwent radical mastectomy with axillary lymph 
node dissection. All primary tumor tissues analyzed were 
taken before initiation of systemic treatment. Six patients 
(37.5%) received adjuvant tamoxifen alone or with 
LHRH analogues, 3 patients (18.75%) received adjuvant 
aromatase inhibitors alone or with LHRH analogues, 
whereas 4 patients (25%) received an adjuvant sequence 
of tamoxifen and aromatase inhibitors with or without 
LHRH analogues. None of the patients, including those 
with HER2-positive tumor, received HER2-targeted 
therapy in the neoadjuvant or adjuvant setting.
Two patients (12.5%) were diagnosed with de novo 
Stage IV BC, whereas the other 14 patients (87.5%) 
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Table 1: Patients and sample characteristics
Patient 
number
Age at 
diagnosis
Primary tumor 
molecular subtype
Primary tumor 
characteristics TNM
Stage at 
diagnosis Sites of relapse Biopsy of the relapse
Relapse 
characterisitics
Patient 1 56 LUMINAL A-like
CDI G3, ER 50%, PR 
70%, 
MIB1 20%, HER2 
negative
pT2pN1(3/17)M0      IIB SKIN (Local Relapse) SKIN NODULE EXCISION
ER 100%, PR 20%, 
HER2 negative
Patient 2 35 LUMINAL B-like (HER2+)
CDI G3, ER 60%, 
PR 2%, 
MIB1 ?, HER2 positive
pT2(25mm)pN0(0/24)
M0    
IIA LUNG
SINGLE LUNG 
NODULE 
RESECTION
ER 95%, PR 95%, 
HER2 positive
Patient 3 45 LUMINAL B-like
CLI G3, ER 90%, PR 
90%, 
MIB1 50%, HER2 
negative
pT2(multif)pN1(1/15)
M0 
IIB SKIN (Local Relapse) SKIN PUNCH ER 90%, PR 60%, HER2 negative
Patient 4 56 LUMINAL A-like
CDI G2, ER 95%, PR 
95%, 
MIB1 8%, HER2 
negative
pT2pN3(11/13)M1   IV BONE, SKIN (Scalp) SKIN PUNCH
ER 90%, PR 50%, 
MIB 20%, HER2 
negative
Patient 5 52 LUMINAL A-like
CDI G2, ER 90%, PR 
80%, 
MIB1 15%, HER2 
negative
pT1cpN1(1/19)M0     IIA
IPSILATERAL 
AXILLARY LYMPH 
NODES, BONE, 
LIVER
IPSILATERAL 
AXILLARY LYMPH 
NODES
ER 10%, PR 1%, 
HER2 negative
Patient 6 71 LUMINAL B-like (HER2+)
CDI G3, ER 100%, 
PR 10%, 
MIB1 15%, HER2 
positive
pT1cpN0M0                    IA
IPSILATERAL 
SUPRACLAVICULAR 
LYMPH NODES
IPSILATERAL 
SUPRACLAVICULAR 
LYMPH NODES
ER 90%, PR 1%, 
HER2 positive
Patient 7 57 LUMINAL A-like
CDI G3, ER 90%, PR 
40%, 
MIB1 8%, HER2 
negative
pT2,pN3(17/33),M1   IV
CONTRALATERAL 
AXILLARY LYMPH 
NODES, BONE
CONTRALATERAL 
AXILLARY LYMPH 
NODES
ER 0%, PR 0%,  
HER2 negative
Patient 8 47 LUMINAL A-like
CDI G3, ER 85%, 
PR 9%, 
MIB1 16%, HER2 
negative
pT1cpN1(2/20)M0         IIA
CONTRALATERAL 
AXILLARY LYMPH 
NODES
CONTRALATERAL 
AXILLARY LYMPH 
NODES
ER 100%, PR 
100%, 
HER2 negative
Patient 9 73 LUMINAL A-like
CDI G2, ER 100%, 
PR 90%, 
MIB1 15%, HER2 
negative
pT1cpN0M0                    IA BONE, LUNG, LIVER, 
LYMPH NODES
LIVER
ER 85%, PgR 0%, 
MIB1 10%, HER2 
negative
Patient 10 71 LUMINAL B-like (HER2+)
CDI G3, ER 15%, 
PR neg, 
MIB1 10%, HER2 
positive
pT2,pN3(39/39),M0 IIIC
LYMPH NODES, 
IPSILATERAL CHEST 
WALL
IPSILATERAL 
CHEST WALL
ER neg, PR neg, 
HER2 positive
Patient 11 56 LUMINAL B-like
CDI G2, ER 98%, 
PR 0%, 
MIB1 25%, HER2 
negative
pT1c(multif),pN0,M0   IA
IPSILATERAL 
AXILLARY LYMPH 
NODES
IPSILATERAL 
AXILLARY LYMPH 
NODES
ER 15%, PR neg, 
MIB1 40%, HER2 
negative
Patient 12 81 LUMINAL B-like
CLI G3, ER 80%, PR 
<1%, 
MIB1 15%, HER2 
negative
cT3,cN+,M0 IIIA
BREAST, LYMPH 
NODES, BONE, 
LIVER
IPSILATERAL 
MASTECTOMY
ER neg, PR neg, 
MIB1 40%, HER2 
negative
Patient 13 61 LUMINAL B-like
CLI G3, ER 90%, PR 
90%, 
MIB1 70%, HER2 
negative
pT2,pN0(0/19),M0 IIA
BREAST, 
IPSILATERAL 
AXILLARY SOFT 
TISSUES
IPSILATERAL 
AXILLARY SOFT 
TISSUES
ER 50%, PR neg, 
MIB1 25%, HER2 
positive
Patient 14 48 LUMINAL B-like
CDI G3, ER 95%, PR 
95%, 
MIB1 80%, HER2 
negative
cT3,cN+,M0 IIIA BONE, LUNG, LIVER, 
LYMPH NODES
LIVER
ER 95%, PR 3%, 
MIB1 30%, HER2 
negative
Patient 15 53 LUMINAL B-like (HER2+)
CDI G3, ER 90%, PR 
30%, 
MIB1 10%, HER2 
positive
pT1c,pN2(6/16),M0     IIIA
IPSILATERAL 
BREAST 
(CUTANEOUS)
IPSILATERAL 
BREAST SKIN 
PUNCH
ER 90%, PR neg, 
MIB1 25%, HER2 
positive
Patient 16 45 LUMINAL B-like
CDI G3, ER 90%, 
PR 1%, 
MIB1 40%, HER2 
negative
IBC cT4cN+M0 
(right) IIIB
CONTRALATERAL 
BREAST, RIGHT 
CHEST WALL, BONE 
RIGHT CHEST WALL
ER 30%, PR neg, 
MIB1 20%, HER2 
negative
Discordant ER, PR and HER2 reported in red.
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developed loco-regional or distant recurrence after 
receiving treatment for primary BC and particularly during 
neo/adjuvant endocrine therapies. The median disease-free 
survival (DFS) time for these patients was 35.38 months 
(range 3–58) from surgery or from the end of adjuvant 
chemotherapy. In more details, 4 patients (25%) had 
primary resistance to endocrine therapy, i.e. they relapsed 
while on the first 2 years of adjuvant endocrine therapy, or 
progressed within the first 6 months of first-line endocrine 
therapy. On the other hand, the other 12 patients (75%) 
developed secondary endocrine resistance. 
Among the 16 patients, 32 breast tumors were 
profiled, including 16 primary breast tumors, 10 loco-
regional recurrences (ipsilateral breast, chest wall or 
supraclavicular/axillary lymph nodes) and 6 distant 
metastases (skin, contralateral axillary lymph nodes, 
liver and lung). Fourteen patients (87.5%) showed at 
least one mutation in one of the 25 genes involved in the 
mechanisms of targeted treatment resistance. Five patients 
(31.25%) had only one mutated gene, 2 patients (12.5%) 
had two mutated genes, whereas the other 7 patients (50%) 
had three or more mutated genes. Overall, we found 64 
mutated genes in 16 primary tumors (Figure 1). The most 
common mutation detected in primary tumor tissues was 
PIK3CA (6 patients, 37.5%), followed by ERBB2, mTOR 
and INPP4B (5 patients for each one, 31.25%) (Figure 1).
Predictive value of relapse mutations
Among the 16 patients, 10 developed loco-regional 
recurrences in the previously operated breast or chest 
wall or in the ipsilateral supraclavicular/axillary lymph 
nodes, whereas 10 patients developed distant metastases 
(bone, skin, lymph nodes, liver and lung). As far as tissue 
samples are concerned, 10 loco-regional recurrences and 6 
distant metastases have been profiled. More precisely, 10 
patients have been biopsied on the site of the first relapse 
during adjuvant treatments, while 5 patients were biopsied 
on a metastatic site in progression under treatment in the 
metastatic setting.
Two patients (12.5%) received only one line of 
therapy in the metastatic setting, while 3 patients (18.75%) 
received two lines of therapy, and the other 11 patients 
(68.75%) received three or more lines of therapy in the 
metastatic setting. Thirteen patients (81.25%) showed 
at least one mutation in one of the 25 genes involved in 
the mechanisms of targeted treatment resistance. Five 
patients (31.25%) had only one mutated gene and 2 
patients (12.5%) had two mutated genes, whereas the other 
6 patients (46.15%) had three or more mutated genes. 
Overall, we found 46 mutated genes in 16 local or distant 
relapses (Figure 2). The most common mutation detected 
in relapsed tissues was PIK3CA (6 patients, 37.5%), 
followed by ERBB2 and MAP2K2 (5 patients for each, 
31.25%) (Figure 2).
Comparison between primary tumor and relapse 
mutations
In four cases (25%), primary tumors and relapsed 
tissues maintained the same mutational profile, whereas 
12 (75%) patients changed pathogenic variants during 
Figure 1: Number of patients for each primary tumor mutation.
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progression. In particular, 9 patients (56.25%) acquired 
new mutations in the metastatic sites, while we find no 
primary tumor mutations in the relapsed tissues of 10 
patients (62.5%). Overall, 5 patients (31.25%) showed 
more mutated genes (Figure 3) and more pathogenic 
variants (Figure 4) in the metastatic sites than in the 
primary tumor tissues. On the other hand, 5 patients 
(31.25%) had more mutated genes (Figure 3) and 6 
(37.5%) had more pathogenic variants (Figure 4) in the 
primary tumor tissues.
Finally, we analyzed the mutations detected in the 
genes that had already shown predictive value in clinical 
trials: PIK3CA, ERBB2, ESR1 and AKT1 genes (Table 2). 
Five out of 6 patients with a PIK3CA mutation in either 
Figure 2: Number of patients for each relapse mutation.
Figure 3: Number of mutated genes in primary tumors and relapsed tissues.
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primary tumor or relapse tissues exhibited one of the 3 
“Hotspot” mutations shown to cause gains in protein 
enzymatic function and induce oncogenic transformation 
(E542 and E545 in the helical domain and H1047 in the 
kinase domain) [19, 20]. The other variants were N1044H, 
N345K, A1035V and V344M (Figure 5). With regard to 
the other genes, we found 11 different pathogenic or likely 
pathogenic variants for ERBB2 (Figure 5), 5 different 
variants for ESR1 and 4 different variants for AKT1 
(Table 2). 
DISCUSSION
Cancer is a dynamic and heterogeneous entity 
following the principles of clonal evolution, with different 
areas of the same primary tumor showing different 
genomic profiles and with metastases acquiring new 
molecular aberrations compared to their primary tumors 
[21–23]. Moreover, clonal heterogeneity, exacerbated by 
the selective pressures imposed by treatment during the 
life cycle of the disease, may confer greater resistance 
on anti-cancer treatments and radiation therapy [24]. 
Acquired drug resistance is common during the course 
of the disease. Therefore, there is an urgent need to 
monitor tumor evolution and ideally predict the onset of 
resistance to targeted therapies. In this context, emerging 
evidence from clinical trials assessing targeted therapies 
demonstrates that the genetic landscape of any given 
tumor will dictate its sensitivity or resistance profile to 
anticancer agents [25]. 
Against this backdrop, we evaluated a panel of 25 
genes involved in targeted treatment resistance, comparing 
cancers sampled at first diagnosis (primary tumors) with 
their matched relapsed sites. Proper understanding of the 
mutational landscape of breast tumors through progression 
and metastatization should open new avenues for the 
assessment of resistance to therapy and the development 
of better targeted treatments, with a potential for improved 
clinical outcomes. The study allowed for the identification 
of the affected genes that were more prevalent in 
recurrences, compared with primary tumors, and that 
might be involved in the resistance to therapies.
In our study, we found an overall detection rate 
of mutations higher than that described in the literature. 
The most frequently mutated genes among the 25 
analyzed were PIK3CA and ERBB2 for both primary 
and relapsed tissues (Figure 5). Mutations of PIK3CA 
were present in 37.5% of primary tumors and relapsed 
tissues, while ERBB2 mutations were present in 31.25% 
of our samples. These percentages are higher than those 
reported in previous research (30% for PIK3CA and 2–3% 
for ERBB2) [26, 27], indicating that our patients have 
been highly selected. It should be noted that only tumors 
Figure 4: Number of pathogenic variants detected in primary tumors and relapsed tissues.
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Table 2: Mutations detected in PIK3CA, ERBB2, ESR1 and AKT1 genes
 Primary tumor mutations Relapse mutations
 PIK3CA ERBB2 ESR1 AKT1 PIK3CA ERBB2 ESR1 AKT1
Patient 2 x x x x x
c.3658G>T, 
p.Gly1220Cys 
(G3658T, 
G1220C)
x x
Patient 4
c.1624G>A, 
p.Glu542Lys 
(G1624A, E542K) 
c.3130A>C, 
p.Asn1044His 
(A3130C, N1044H)
x x x
c.1624G>A, 
p.Glu542Lys 
(G1624A, 
E542K)
x x x
Patient 5
c.3140A>G, 
p.His1047Arg 
(A3140G, H1047R)
x x x
c.3140A>G, 
p.His1047Arg 
(A3140G, 
H1047R)
x x x
Patient 6 x
c.1067C>A, 
p.Ala356Asp 
(C1067A, 
A356D)
x x x
c.1067C>A, 
p.Ala356Asp 
(C1067A, 
A356D)
x x
Patient 7 x
c.-1C>T   
c.2246C>T, 
p.Ser749Phe 
(C2246T, 
S749F)              
c.1816G>A, 
p.Asp606Asn 
(G1816A, 
D606N)
x x x x x x
Patient 8 x x x x x x
c.382G>A, 
p.Val128Met 
(G382A, 
V128M)
c.117G>T, 
p.Lys39Asn 
(G117T, 
K39N)        
c.288-7C>T    
c.656C>T, 
p.Thr219Ile 
(C656T, 
T219I)
Patient 9
c.1624G>A, 
p.Glu542Lys 
(G1624A, E542K)  
c.1035T>A, 
p.Asn345Lys 
(T1035A, N345K)
x x x
 c.1035T>A, 
p.Asn345Lys 
(T1035A, 
N345K)
x x
c.46G>A, 
p.Gly16Arg 
(G46A, 
G16R)
Patient 
10
c.3104C>T, 
p.Ala1035Val 
(C3104T, A1035V)
c.3526C>T, 
p.Gln1176Ter 
(C3616T, 
Q1206X) 
c.1096C>T, 
p.Gln366Ter 
(C1186T, 
Q396X)  
c.1087C>T, 
p.Gln363Ter 
(C1177T, 
Q393X) 
x
c.32G>A, 
p.Trp11Ter 
(G32A, 
W11X) 
x x x x
Patient 
11
c.1633G>A, 
p.Glu545Lys 
(G1633A, E545K)
c.1478C>T, 
p.Pro493Leu 
(C1568T, 
P523L)
x x
c.1633G>A, 
p.Glu545Lys 
(G1633A, 
E545K)
c.1478C>T, 
p.Pro493Leu 
(C1568T, 
P523L)
x x
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with proved targeted treatment resistance, such as those 
relapsing or progressing under the targeted treatment, 
have been included in the study. This process increases 
the chance of finding the mutations responsible for that 
resistance. Other genes mutating with high frequency in 
our study were mTOR and INPP4B, which mutated in 
31.25% of primary tumors, and MAP2K2, which mutated 
in 31.25% of relapsed sites. Overall, the most frequently 
mutated genes among those investigated are involved in 
the PI3K/AKT/mTOR and the MAPK signaling pathways. 
Conversely, mutations in genes involved in the cell-cycle 
regulation are not as crucial to the mechanism of treatment 
resistance.
In 75% of the patients, furthermore, the number and 
type of mutations changed with disease progression, as 
the immunohistochemical profile does in 50% of cases. 
In contrast with the previous literature, however, most 
of the time (68.75% of cases) the mutations detected did 
not increase in number throughout the natural history of 
the tumor. As already described, we included patients 
with targeted treatment resistant tumors. As a result, 
this might have contributed to selecting primary tumors 
with a high rate of mutations. Interestingly, 12 out of 14 
patients (85.71%) with early-stage or locally advanced 
primary tumors showed a mutation in one of the genes 
analyzed. The high rate of mutation detected in primary 
BC tissues might explain the subsequent relapse and thus, 
it might justify a more targeted approach in neoadjuvant or 
adjuvant settings for patients exhibiting these mutations at 
diagnosis. It is noteworthy that previous studies indicated 
better prognoses for early BC patients harboring a PIK3CA 
mutation [28–30]. Along with the results shown by m-TOR 
and PI3K inhibitors in metastatic settings [31, 32], these 
data highlight a possible dual role of PIK3CA mutations in 
early versus advanced settings. In early HR-positive BC, 
PIK3CA may represent a predictive marker for benefit of 
endocrine therapies. In advanced HR-positive BC selected 
by primary endocrine therapy, PIK3CA contribute to 
endocrine resistance requiring combined endocrine and 
targeted therapy (i.e. everolimus or buparlisib). This is a 
research area in which more studies are clearly needed.
According to the results reported in recent clinical 
trials [6, 14, 15], mutations in PIK3CA, ERBB2, AKT1 
and ESR1 genes are able to predict the response to 
some targeted therapies, and future research may find 
further associations. On these grounds, the mutations 
detected in the relapsed tissues/metastatic sites of 11 
patients (68.75%) enrolled in our study could have 
guided subsequent treatment choices in a different way. 
More specifically, these patients underwent the standard 
treatments approved in that period for the metastatic 
setting. Nevertheless, 6 patients with PIK3CA mutations 
could have benefited from treatment with Everolimus, 
Buparlisib or Taselisib in their capacity as approved 
agents or in the context of clinical trials. Moreover, the 
patient with AKT1 mutations could have benefited from 
Everolimus, while 3 patients with ESR1 mutations could 
have benefited from Fulvestrant. Finally, 5 patients with 
Patient 
12 x x x x
c.3140A>G, 
p.His1047Arg 
(A3140G, 
H1047R)
x x x
Patient 
14 x x
c.1469T>G, 
p.Met490Arg 
(T1469G, 
M490R)
x x c.135+3G>T
c.600G>C,p.
Trp200Cys 
(G600C, 
W200C) 
c.1048G>A, 
p.Ala350Thr 
(G1048A, 
A350T) 
c.1469T>G, 
p.Met490Arg 
(T1469G, 
M490R)
x
Patient 
15 x
c.1870A>G, 
p.Ile624Val 
(A1960G, 
I654V)
x x x
c.1870A>G, 
p.Ile624Val 
(A1960G, 
I654V)
x x
Patient 
16
c.1030G>A, 
p.Val344Met 
(G1030A, V344M)  
c.3140A>G, 
p.His1047Arg 
(A3140G, H1047R)
x x x
c.1030G>A, 
p.Val344Met 
(G1030A, 
V344M) 
c.3140A>G, 
p.His1047Arg 
(A3140G, 
H1047R)
x c.1370-26C>G x
PIK3CA “Hotspot” mutations reported in red.
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ERBB2 mutations could have benefited from treatment 
with Neratinib (Table 2). 
In spite of such evidence, our study presents several 
limitations and must be considered hypothesis-generating. 
First of all, our study population is still small in sample 
size and the relapsed sites were biopsied at various time 
points throughout tumor course. Secondly, as patients 
were chosen based on sample availability, there may be 
inherent biases in patient selection. Furthermore, due to 
the retrospective nature of our analysis, samples were 
fixed and processed for storage in different periods and 
by different technicians, with no purpose of genomic 
analysis. This variability might have reduced the quality 
and preservation of some tissues, increasing the rate of 
variants detected in some of the samples. Overall, we 
described mutations with an allelic burden ≥3%. This was 
the case because, for research purposes, we wanted to 
describe the highest possible number of mutations present 
in our samples. Nevertheless, in some samples with a 
lower DNA quality we found a high number of variants, 
therefore we decided to use the cut-off of 5%. This is the 
detection limit of Sanger sequencing, the technique used 
in clinical practice for the confirmation of NGS variant 
calls. Future research should be conducted to clarify the 
predictive role of each mutation for each targeted therapy 
and define the cut-off level for test positivity, in order 
to select which patients would benefit most from that 
targeted treatment.
The re-characterization of recurrences was provided 
through invasive tumor biopsies, as the standard of 
practice. Obtaining samples of metastatic tissue is notably 
impractical and complicated by spatial heterogeneity 
and sampling bias. An attractive alternative to overcome 
the limitation of repeated tissue sampling is provided by 
peripheral blood samples as a ‘liquid biopsy’ through the 
analyses of CTCs, ctDNA or exosomes. Nevertheless, 
tumor heterogeneity, different sequencing techniques, 
spatial as well as temporal factors, and potential germline 
DNA contamination may cause low rates of concordance 
between liquid biopsies and tumor tissue. So far, therefore, 
both tissue and blood-based NGS are necessary to describe 
the complex biology of BC [33]. Finally, our study only 
focused on gene mutations, but the recent development 
of additional high information content assays focused on 
Figure 5: Mutations detected in the two most frequently mutated genes, PIK3CA and ERBB2.
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abnormalities in DNA methylation, microRNA expression 
and protein expression can provide further opportunities to 
better characterize the molecular architecture of BC. 
The ability to perform NGS on small FFPE 
samples, such as core biopsies, creates the opportunity 
to comprehensively characterize cancer-relevant genes 
and personalize therapies. Overall, our study leads to the 
following conclusions: 
1. Almost all patients had at least one alteration 
potentially targetable with approved or investigational 
therapeutics. This finding indicates that routine genomic 
profiling may be instrumental in individualized pathway-
directed therapies. 
2. Our study reveals substantial discordances 
between primary tumors and metastases, which stresses 
the need for analysis of metastatic tissue at recurrences. 
The analysis of recurrent tumors prior to selecting 
treatment may provide additional insights, as both gains 
and losses of targets are observed. Furthermore, the 
analysis could contribute to treatment selection. In this 
setting, the role of liquid biopsy instead of biopsy of the 
metastatic site should be further investigated.
3. Overall, the most frequently mutated genes 
among those investigated were involved in the PI3K/AKT/
mTOR and the MAPK signaling pathway. It is likely that 
the deregulation of these pathways plays a crucial role in 
the mechanisms of targeted treatment resistance. Future 
research should be conducted to identify patients with a 
molecular profile predictive of treatment resistance, which 
makes them eligible for more intensive and personalized 
adjuvant treatments. 
4. The extreme complexity of cancer biology 
necessitates analysis not only on a single level, as the novel 
targets for molecularly targeted therapy can be revealed at 
a DNA, RNA and protein level, or epigenetically.
Whether these alterations drive disease progression as 
well as survival, and therefore represent suitable therapeutic 
targets for the treatment of metastatic BC or for adjuvant 
therapy aimed at preventing a relapse warrants further study. 
However, our study demonstrates that mutation events may 
be present at diagnosis or arise during cancer treatment. 
Thus, profiling primary and metastatic tumor tissues may be 
a major step in defining optimal treatments for BC patients. 
MATERIALS AND METHODS
Study design
Patients affected by metastatic hormone receptor 
(HR) positive and/or HER2 positive BC were eligible 
for the study. In order to be enrolled, patients had to have 
tissue samples taken from the primary tumor and at least 
one relapsed site stored in the archives of our Pathology 
Department. Using a next-generation sequencing (NGS) 
technology, the Ion Torrent Personalized Genome Machine 
(PGM) (Life Technologies, Guilford, CT, USA), we 
evaluated a panel of 25 genes involved in the mechanisms 
of endocrine and targeted treatment resistance. We 
analyzed formalin-fixed and paraffin-embedded (FFPE) 
tissues of primary BCs and the matched tissues taken from 
local or distant relapsed sites. Therefore, we compared the 
cancer genes found in cancers sampled at first diagnosis 
(primary tumors) with those found in relapsed cancers, 
after progression during treatment. The study was 
approved by our local research ethics committee.
Patients and samples
We retrospectively identified 143 patients affected 
by metastatic hormone positive and/or HER2 positive BC, 
treated at the Modena Cancer Center in the last 20 years 
(Figure 6). Among these patients, 65 relapsed or developed 
disease progression during a targeted treatment, including 
endocrine therapy. Thirty of these patients had formalin-
fixed and paraffin-embedded (FFPE) tissues taken from 
the primary tumor and from the local or distant recurrence 
stored in the archives of our Pathology Department. 
The FFPE samples were evaluated by a pathologist for 
specimen suitability, tumor quality and quantity, and 
selection of tumor areas for microdissection. Finally, only 
21 patients gave consent to the use of their stored tissues 
for the study and were therefore included in the analyses. 
DNA was purified from 6 to 8 5 μm-thin sections 
of each FFPE tissue using the Maxwell® 16 FFPE 
Plus LEV DNA Purification Kit on the Maxwell® 16 
System (Promega). DNA sample quality and quantity 
were assessed through a Qubit 2.0 fluorometer and the 
Qubit™ dsDNA HS Assay Kit (ThermoFisher), in order 
not to overestimate the concentration of stressed FFPE-
purified DNAs. In 16 out of 21 patients, the extraction 
was successful and the purified DNA was adequate for the 
sequencing. 
Finally, DNA was successfully extracted from 32 
FFPE blocks stored between 2000 and 2016. According 
to data reported by previous research, all of these FFPE 
blocks were considered suitable for DNA extraction 
[34]. In particular, 5 primary BC tissues were stored 
between 2000 and 2005, 8 specimens were stored 
between 2006 and 2010 and 3 specimens were stored 
between 2011 and 2016. Of secondary cancer tissues, 
only one was stored in 2004, 3 FFPE blocks were stored 
between 2006 and 2010, while 12 were stored between 
2011 and 2016.
The multi-gene panel
Twenty-five genes involved in the mechanisms 
of targeted treatment resistance were selected for the 
analyses. The list of genes and their role in treatment 
resistance are reported in Table 3 and described below: 
• EGFR, ERBB2 and ERBB3: this family of 
tyrosine kinase receptors is involved in cell proliferation 
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control, differentiation and survival [35]. The mutation 
rate of ERBB2 in BC is about 2–3% [27]. 
• IGF1R, FGFR1, MET: in HR and/or HER2 
positive BC, one of the possible mechanisms of resistance 
to endocrine and anti-HER2 agents is alternative signaling 
from other receptor tyrosine kinases [6]. 
• AKT1, PDK1, mTOR, PIK3CA, PIK3R1, PTEN, 
INPP4B: the PI3K/AKT/mTOR pathway is one of the main 
downstream pathways involved in cancer cell proliferation. 
Mutations of PIK3CA have been found in almost 30% of 
all sporadic BC [26] with a wide frequency range in BC 
subtypes [36, 37]. The majority of the mutations, “Hotspot” 
mutation, occurred in three sites: E542 and E545 in the 
helical domain, and H1047 in the kinase domain. These 
mutations cause gains in protein enzymatic function and 
induce oncogenic transformation [19, 20]. The somatic 
intragenic PTEN mutation frequency is <5% [38]. 
• BRAF, KRAS, MEK1 (MAP2K1), MEK2 
(MAP2K2), ERK1 (MAPK3), ERK2 (MAPK1): the MAPK 
signaling pathway may lead to uncontrolled cell cycle, 
resistance to apoptosis and to chemotherapy, targeted 
therapies and radiotherapy [6].
Figure 6: Flow diagram of patients evaluated for the study.
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• CCDN1, CCDN2, CCDN3, CDK4, CDK6: 
dysregulation of the cell-cycle machinery and activation 
of cyclin-dependent kinases (CDKs) represents one of 
the mechanisms of endocrine resistance. Following the 
literature, however, the mutation rate of these genes seems 
to be very low.
• ESR1: in HR positive BC, multiple mechanisms 
of endocrine resistance have been described, including 
mutations in the ESR1 gene. Mutations in ESR1 appear to 
be rare in treatment naive settings (up to 3% of primary 
tumors [39]) and more frequent in advanced BC (12.1% 
of a large cohort of advanced BC [40]).
Study procedures
The Ion AmpliSeq™ technology (Thermo Fisher 
Scientific, Waltham, MA USA 02451) was used to design 
the gene panel described above. An optimized primer 
design for the FFPE samples encompassing the CDS and 
the UTR regions of the selected genes was created, in 
order to generate amplicons up to 175 bp. Libraries were 
prepared using the Ion AmpliSeq™ Library Kit 2.0 starting 
from 15 ng of gDNA/pool, according to the manufacturer’s 
instructions. Template preparation was performed using 
an Ion OneTouch™ 2 System following the latest version 
of the manufacturer’s manuals. The template positive 
Ion Sphere Particles (ISPs+) were sequenced on an Ion 
Torrent™ Personal Genome Machine® (PGM™) System 
(Life Technologies Ltd, Paisley, UK) using the Ion 318™ 
Chip kit v2 following the Ion PGM™ Sequencing 200 
Kit v2 manual. Run conditions were optimized to have 
at least 1000X coverage depth for 90% of target regions. 
In these conditions, LoD for mutation was about 1%. For 
the purpose of quality run assessment, we considered 
suitable for bioinformatics analysis only data coming 
from sequencing runs with the following run metrics: 
on-target % of reads >85%, amplicons with at least 1000 
reads >90% and amplicon with no strand bias >95%. NGS 
sequence data were analyzed, processed and annotated as 
already described [41].
Statistical analysis
Patient and tumor characteristics were retrieved 
from the electronic medical files of all patients. Data were 
summarized by frequency and percentage for categorical 
variables, and by median and range for continuous 
variables. The median disease-free survival (DFS) time 
for these patients was determined as the interval from 
surgery, or from the end of adjuvant chemotherapy, to any 
BC event including local, regional or distant recurrence or 
contralateral disease. 
The bioinformatics analyses identified recurrently 
mutated genes in primary tumors and relapsed tissues. 
Using our NGS run conditions, we considered known 
pathogenic and likely pathogenic variants as reported 
in the literature so far, with an allelic burden ≥3%. For 
samples with lower DNA quality, we only considered 
pathogenic or likely pathogenic variants with an allelic 
burden (mutation frequency) ≥5%.
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